|Bid||129.00 x 0|
|Ask||129.50 x 0|
|Day's Range||127.50 - 127.50|
|52 Week Range||80.41 - 142.61|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 99,563 shares of VRTX on 01/16/2018 at an average price of $156.99 a share.
Vertex Pharmaceuticals (NASDAQ: VRTX ) releases its next round of earnings Monday, Jan. 8. Here's Benzinga's essential guide to Vertex's Q4 earnings report. Earnings and Revenue Based on Vertex management ...
In a note on Tuesday, Geoffrey Porges at Leerink Partners identified Vertex Pharmaceuticals (VRTX) and Alexion Pharmaceuticals (ALXN) as his top two picks among large cap biotechs in 2018, citing their continued dominance in two medical areas. Alexion is slated to move into its new headquarters in Boston’s Seaport District in mid-2018, a couple blocks from where Vertex is located. In his note, Porges said that both Vertex and Alexion are poised to thrive in what he predicts will be a tough environment for Big Pharma, characterized by “hyper-competition, pricing pressure and uncertain M&A activity.” According to Porges, that's because both companies focus on diseases — cystic fibrosis for Vertex, and a rare blood disorder in the case of Alexion — for which there are relatively few serious competitors.
NEW YORK, NY / ACCESSWIRE / December 14, 2017 / Teva shares sank almost 5% yesterday after traders showed concern over calls for protest in Israel over the company planning on cutting thousands of jobs ...
Deutsche Bank said "chances of a Vertex takeout are as good as at any point in the company's history."
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology.
CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 125,000 shares of VRTX on 12/11/2017 at an average price of $141.35 a share.
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety ...
NEW YORK, Nov. 15, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Barracuda ...
Research Desk Line-up: Esperion Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Vertex Pharmaceuticals ...
After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.
The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) both dropped more than 2%, led lower by a host of disappointing financial results from several big drug makers. The main culprit in today’s pullback is Celgene (CELG). Adding to the pain, Celgene cut its vaunted 2020 sales outlook to a range of $19 billion to $20 billion from the previous target of $21 billion.
Vertex Pharmaceuticals Inc reported a wider third-quarter net loss on Wednesday, on higher costs and onetime items, and raised its outlook for full-year sales of its key cystic fibrosis drugs. The Cambridge, Massachusetts-based biotechnology company posted a net loss of $103 million, or 41 cents a share, compared with a loss of $39 million, or 16 cents a share, a year earlier. Excluding one-time items, Vertex said it earned 53 cents per share.
Vertex Pharmaceuticals Inc., on the brink of a breakthrough that could treat nearly all patients with cystic fibrosis, has done everything an investor could ask for in 2017, including double its market ...
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals' (ALXN) Soliris.
Analysts at BTIG laid out the bullish case for owning shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) — a "storied" company with a strong growth outlook. BTIG's Dane Leone initiates ...
The Vetr crowd on Wednesday downgraded its rating of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) from 5 stars (Strong Buy), issued 15 days ago, to 1 star (Strong Sell). Crowd sentiment at the time ...